Vaginal Slings Market Size is projected to increase substantially from 2022-2028, as a result of the growing awareness about the benefits of surgery over other treatments for stress urinary incontinence (SUI) in women. Moreover, the rising female geriatric population will also augment industry size, as incontinence symptoms can occur frequently during menopause. Vaginal or urethral sling refers to a procedure used to treat SUI, an underreported and underdiagnosed medical problem that affects 15%-60% of women. This procedure is designed to close the urethra and bladder neck to control urine leakage. It uses various materials, including man-made materials known as mesh and tissue from the body.
High emphasis on increasing public healthcare spending and the strong focus on reducing maternal death cases are among the key factors fostering the vaginal slings market trends through 2022-2028. The WHO and UNFPA, for example, launched five critical targets to reduce preventable maternal deaths, which could augment the need for the urethral vaginal sling, as incontinence issues may arise during pregnancy and after childbirth. However, a decline in the number of women seeking medical evaluation and treatment for urinary incontinence due to social stigma, alongside the potential risks associated with vaginal sling surgery like urinary tract infections, may hinder industry growth to a certain extent.
With regards to end-use, the hospitals segment is expected to account for a major share in the vaginal slings market by 2028, given the significant introduction of robot-assisted minimally invasive surgery in hospital settings. In 2021, the Biden Administration launched $500 million funds from the American Rescue Act, with an objective to help rural hospitals and support the renovation and construction of rural healthcare facilities. Developments such as these, along with the gradual increase in surgery rate in U.S. hospitals, are also likely to propel the overall market dynamics in the upcoming years.
Regionally, the Europe vaginal slings market will record an appreciable revenue by 2028, considering the high prevalence of urinary tract infections among women in the UK. As per the National Health Service’s data, nearly 3-6 million people have some degree of urinary incontinence in the UK. This disease prevalence, coupled with the introduction of innovative devices for minimally invasive surgeries, will push the demand for vaginal mesh sling procedures over the estimated timeline.
Betatech Medical, Meta Biomed, Promedon, Aspide Medical (IPSA Group), DynaMesh, Herniamesh, Cousin Biotech, Neomedic International, Helioscopie, ABISS, Sofradim, B. Braun Melsungen, Covidien (Medtronic), Caldera Medical, Cook Medical, American Medical Systems (Bostin Scientific), Ethicon (Johnson & Johnson), C. R. Bard (BD), Boston Scientific, and Coloplast are some of the prominent players operating in the vaginal slings market. These industry participants are focusing on new product launches, acquisitions, and mergers to strengthen their presence in the global market. For instance, in December 2021, Caldera Medical expanded its Desara family of pelvic sling systems with the launch of Desara TVez, designed to treat women with SUI and other pelvic health disorders.
Apart from the economic crisis, the novel coronavirus pandemic has led to a decline in the number of elective surgeries being performed worldwide, which may have negatively impacted the vaginal slings industry. Despite these challenges, the industry may regain traction over the foreseeable future, owing to the neurological implications associated with the virus. Some of the neurological symptoms reported in COVID-19 patients include demyelinating neuropathy and inflammation. Various research studies have revealed that the demyelination in the pudendal nerve could lead to bladder incontinence which could, in turn, amplify demand for vaginal sling procedures worldwide.
Market, by Type
Market, by End-use
The above information is provided for the following regions and countries: